Author:
Pedley R. Barbara,Tozer Gillian M.
Reference114 articles.
1. Algire GH (1943) An adaptation of the transparent-chamber technique to the mouse. J Nat Cancer Inst 4: 1–11.
2. Anderson HL, Yap JT, Miller MP et al. (2003) Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 21: 2823–30.
3. Beauregard DA, Thelwall PE, Chaplin DJ et al. (1998) Magnetic resonance imaging and spectroscopy of combretastain A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 77: 1761–67.
4. Beauregard DA, Hill SA, Chaplin DJ et al. (2001) The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 61: 6811–5.
5. Beauregard DA, Pedley RB, Hill SA et al. (2002) Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed 15: 99–105.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献